Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 413

1.

A History of Nuclear Medicine in the UK Radionuclide Investigation of the Brain.

Ell PJ.

In: McCready R, Gnanasegaran G, Bomanji JB, editors. A History of Radionuclide Studies in the UK: 50th Anniversary of the British Nuclear Medicine Society [Internet]. Cham (CH): Springer; 2016. Chapter 7.
2016 Mar 10.

2.

The Institute of Nuclear Medicine London.

Bomanji J, Ell PJ.

In: McCready R, Gnanasegaran G, Bomanji JB, editors. A History of Radionuclide Studies in the UK: 50th Anniversary of the British Nuclear Medicine Society [Internet]. Cham (CH): Springer; 2016. Chapter 6.
2016 Mar 10.

3.

Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF).

Win T, Screaton NJ, Porter JC, Ganeshan B, Maher TM, Fraioli F, Endozo R, Shortman RI, Hurrell L, Holman BF, Thielemans K, Rashidnasab A, Hutton BF, Lukey PT, Flynn A, Ell PJ, Groves AM.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):806-815. doi: 10.1007/s00259-017-3917-8. Epub 2018 Jan 16.

PMID:
29335764
4.

Obituary.

Ell PJ.

Nucl Med Commun. 2015 Dec;36(12):1270. No abstract available.

PMID:
26819973
5.

The contribution of medical physics to nuclear medicine: a physician's perspective.

Ell PJ.

EJNMMI Phys. 2014 Dec;1(1):3. doi: 10.1186/2197-7364-1-3. Epub 2014 May 1.

6.

The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.

Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J.

J Nucl Med. 2016 Jan;57(1):34-40. doi: 10.2967/jnumed.115.166017. Epub 2015 Oct 15.

7.

Simultaneous PET-MRI Studies of the Concordance of Atrophy and Hypometabolism in Syndromic Variants of Alzheimer's Disease and Frontotemporal Dementia: An Extended Case Series.

Moodley KK, Perani D, Minati L, Della Rosa PA, Pennycook F, Dickson JC, Barnes A, Contarino VE, Michopoulou S, D'Incerti L, Good C, Fallanca F, Vanoli EG, Ell PJ, Chan D.

J Alzheimers Dis. 2015;46(3):639-53. doi: 10.3233/JAD-150151.

PMID:
26402512
8.

Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.

Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C, Ell PJ, Seufert J, Gloor B, Perren A, Reubi JC, Forrer F.

Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22. doi: 10.1016/S2213-8587(13)70049-4. Epub 2013 Jul 25.

9.

Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer.

Miles KA, Ganeshan B, Rodriguez-Justo M, Goh VJ, Ziauddin Z, Engledow A, Meagher M, Endozo R, Taylor SA, Halligan S, Ell PJ, Groves AM.

J Nucl Med. 2014 Mar;55(3):386-91. doi: 10.2967/jnumed.113.120485. Epub 2014 Feb 10.

10.

Clinical evaluation of reducing acquisition time on single-photon emission computed tomography image quality using proprietary resolution recovery software.

Aldridge MD, Waddington WW, Dickson JC, Prakash V, Ell PJ, Bomanji JB.

Nucl Med Commun. 2013 Nov;34(11):1116-23. doi: 10.1097/MNM.0b013e3283658328.

PMID:
24056385
11.

Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients.

Win T, Thomas BA, Lambrou T, Hutton BF, Screaton NJ, Porter JC, Maher TM, Endozo R, Shortman RI, Afaq A, Lukey P, Ell PJ, Groves AM.

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):337-42. doi: 10.1007/s00259-013-2514-8. Epub 2013 Aug 14.

12.

Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer.

Win T, Miles KA, Janes SM, Ganeshan B, Shastry M, Endozo R, Meagher M, Shortman RI, Wan S, Kayani I, Ell PJ, Groves AM.

Clin Cancer Res. 2013 Jul 1;19(13):3591-9. doi: 10.1158/1078-0432.CCR-12-1307. Epub 2013 May 9.

13.

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.

J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.

14.

Simultaneous PET/MRI in frontotemporal dementia.

Moodley KK, Minati L, Barnes A, Dickson JC, Ell PJ, Chan D.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):468-9. doi: 10.1007/s00259-012-2315-5. Epub 2012 Dec 12. No abstract available.

PMID:
23232508
15.

Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma.

Shastry M, Miles KA, Win T, Janes SM, Endozo R, Meagher M, Ell PJ, Groves AM.

Mol Imaging. 2012 Sep-Oct;11(5):353-60.

16.

Defining the role of PET-CT in staging early breast cancer.

Groves AM, Shastry M, Ben-Haim S, Kayani I, Malhotra A, Davidson T, Kelleher T, Whittaker D, Meagher M, Holloway B, Warren RM, Ell PJ, Keshtgar MR.

Oncologist. 2012;17(5):613-9. doi: 10.1634/theoncologist.2011-0270. Epub 2012 Apr 26.

17.

Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[18F]fluoro-D-glucose.

Win T, Screaton NJ, Porter J, Endozo R, Wild D, Kayani I, Dickson J, Shortman RI, Reubi JC, Ell PJ, Groves AM.

Mol Imaging. 2012 Apr;11(2):91-8.

PMID:
22469237
18.

The role of 18FDG PET/CT in the management of colorectal liver metastases.

Engledow AH, Skipworth JR, Pakzad F, Imber C, Ell PJ, Groves AM.

HPB (Oxford). 2012 Jan;14(1):20-5. doi: 10.1111/j.1477-2574.2011.00378.x. Epub 2011 Nov 14.

19.

Investigating vulnerable atheroma using combined (18)F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation.

Menezes LJ, Kotze CW, Agu O, Richards T, Brookes J, Goh VJ, Rodriguez-Justo M, Endozo R, Harvey R, Yusuf SW, Ell PJ, Groves AM.

J Nucl Med. 2011 Nov;52(11):1698-703. doi: 10.2967/jnumed.111.093724. Epub 2011 Oct 11.

20.

Delivering affordable cancer care in high-income countries.

Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M.

Lancet Oncol. 2011 Sep;12(10):933-80. doi: 10.1016/S1470-2045(11)70141-3.

PMID:
21958503
21.

Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.

Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, Seufert J, Weber WA, Bomanji J, Perren A, Ell PJ, Reubi JC.

J Nucl Med. 2011 Jul;52(7):1073-8. doi: 10.2967/jnumed.110.085142. Epub 2011 Jun 16.

22.

What is the relationship between ¹⁸F-FDG aortic aneurysm uptake on PET/CT and future growth rate?

Kotze CW, Groves AM, Menezes LJ, Harvey R, Endozo R, Kayani IA, Ell PJ, Yusuf SW.

Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1493-9. doi: 10.1007/s00259-011-1799-8. Epub 2011 Apr 6.

PMID:
21468762
23.

Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study.

Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S, Murray RM.

J Psychopharmacol. 2011 Nov;25(11):1462-8. doi: 10.1177/0269881110382465. Epub 2010 Sep 17.

PMID:
20851843
24.

¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.

Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, Kelleher T, Miles KA, Ell PJ, Keshtgar MR.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):46-52. doi: 10.1007/s00259-010-1590-2. Epub 2010 Aug 14.

PMID:
20711577
25.

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR.

J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914.

26.

Nonlaxative PET/CT colonography: feasibility, acceptability, and pilot performance in patients at higher risk of colonic neoplasia.

Taylor SA, Bomanji JB, Manpanzure L, Robinson C, Groves AM, Dickson J, Papathanasiou ND, Greenhalgh R, Ell PJ, Halligan S.

J Nucl Med. 2010 Jun;51(6):854-61. doi: 10.2967/jnumed.109.072728. Epub 2010 May 19.

27.

Simultaneous dual-radionuclide myocardial perfusion imaging with a solid-state dedicated cardiac camera.

Ben-Haim S, Kacperski K, Hain S, Van Gramberg D, Hutton BF, Erlandsson K, Sharir T, Roth N, Waddington WA, Berman DS, Ell PJ.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1710-21. doi: 10.1007/s00259-010-1441-1. Epub 2010 Apr 11.

28.

What is the natural history of 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque.

Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, Groves AM.

Atherosclerosis. 2010 Jul;211(1):136-40. doi: 10.1016/j.atherosclerosis.2010.01.012. Epub 2010 Jan 22.

PMID:
20202634
29.

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK, Kottaridis PD, Roughton M, Morris EC, Goldstone AH, Linch DC, Ell PJ, Mackinnon S.

Blood. 2010 Apr 8;115(14):2763-8. doi: 10.1182/blood-2009-11-255182. Epub 2010 Feb 2.

30.

The role of ¹⁸fluoro-deoxy glucose combined position emission and computed tomography in the clinical management of anal squamous cell carcinoma.

Engledow AH, Skipworth JR, Blackman G, Groves A, Bomanji J, Warren SJ, Ell PJ, Boulos PB.

Colorectal Dis. 2011 May;13(5):532-7. doi: 10.1111/j.1463-1318.2010.02193.x.

PMID:
20070338
31.

Assessment of left ventricular function at rest using rubidium-82 myocardial perfusion PET: comparison of four software algorithms with simultaneous 64-slice coronary CT angiography.

Menezes LJ, Groves AM, Prvulovich E, Dickson JC, Endozo R, Shastry MH, Kayani IA, Papathanasiou ND, Bomanji JB, Ell PJ.

Nucl Med Commun. 2009 Dec;30(12):918-25. doi: 10.1097/MNM.0b013e328329fc34.

PMID:
19884868
32.

First experience of combined cardiac PET/64-detector CT angiography with invasive angiographic validation.

Groves AM, Speechly-Dick ME, Kayani I, Pugliese F, Endozo R, McEwan J, Menezes LJ, Habib SB, Prvulovich E, Ell PJ.

Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2027-33. doi: 10.1007/s00259-009-1213-y. Epub 2009 Jul 18.

PMID:
19618180
33.

Sentinel node imaging in breast cancer using superficial injections: technical details and observations.

Somasundaram SK, Chicken DW, Waddington WA, Bomanji J, Ell PJ, Keshtgar MR.

Eur J Surg Oncol. 2009 Dec;35(12):1250-6. doi: 10.1016/j.ejso.2009.05.006. Epub 2009 Jun 21.

PMID:
19540710
34.

Vascular inflammation imaging with 18F-FDG PET/CT: when to image?

Menezes LJ, Kotze CW, Hutton BF, Endozo R, Dickson JC, Cullum I, Yusuf SW, Ell PJ, Groves AM.

J Nucl Med. 2009 Jun;50(6):854-7. doi: 10.2967/jnumed.108.061432. Epub 2009 May 14.

35.

The incremental value of dual modality PET/CT imaging over PET imaging alone in advanced colorectal cancer.

Engledow AH, Bond-Smith GE, Francis D, Pakzad F, Bomanji J, Groves A, Ell PJ.

Indian J Surg. 2009 Apr;71(2):63-8. doi: 10.1007/s12262-009-0018-3. Epub 2009 May 2.

36.

Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT.

Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, Kayani I, Menezes LJ, Dickson JC, Ell PJ.

J Nucl Med. 2009 Apr;50(4):538-45. doi: 10.2967/jnumed.108.057901. Epub 2009 Mar 16.

37.

Increased metabolic activity in abdominal aortic aneurysm detected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT).

Kotze CW, Menezes LJ, Endozo R, Groves AM, Ell PJ, Yusuf SW.

Eur J Vasc Endovasc Surg. 2009 Jul;38(1):93-9. doi: 10.1016/j.ejvs.2008.12.016. Epub 2009 Feb 12.

38.

Clinical governance improves the quality of nuclear medicine reporting.

Peters AM, Bomanji J, Ell PJ, Gordon I, Hilson AJ, Murrain C.

Nucl Med Commun. 2008 Nov;29(11):999-1001. doi: 10.1097/MNM.0b013e32830ebd01.

PMID:
18836379
39.

Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.

Groves AM, Wishart GC, Shastry M, Moyle P, Iddles S, Britton P, Gaskarth M, Warren RM, Ell PJ, Miles KA.

Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):416-21. doi: 10.1007/s00259-008-0948-1. Epub 2008 Sep 26.

PMID:
18818917
40.

CT coronary angiography: quantitative assessment of myocardial perfusion using test bolus data-initial experience.

Groves AM, Goh V, Rajasekharan S, Kayani I, Endozo R, Dickson JC, Menezes LJ, Shastry M, Habib SB, Ell PJ, Hutton BF.

Eur Radiol. 2008 Oct;18(10):2155-63. doi: 10.1007/s00330-008-0987-9. Epub 2008 May 9.

PMID:
18465134
41.

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.

Cancer. 2008 Jun;112(11):2447-55. doi: 10.1002/cncr.23469.

42.

Sugar rush: the early days of molecular imaging.

Ell PJ.

Lancet Oncol. 2008 Apr;9(4):400. doi: 10.1016/S1470-2045(08)70102-5. No abstract available.

PMID:
18374294
43.

How do patients perceive the benefits and risks of peripheral angioplasty? Implications for informed consent.

Habib SB, Sonoda L, See TC, Ell PJ, Groves AM.

J Vasc Interv Radiol. 2008 Feb;19(2 Pt 1):177-81. doi: 10.1016/j.jvir.2007.10.016.

PMID:
18341945
44.

Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumour.

Haba Y, Williams MV, Neal DE, Ong JY, Ostrowski MJ, Ell PJ, Nargund V, Shamash J, Oliver RT.

BJU Int. 2008 Mar;101(5):570-4. doi: 10.1111/j.1464-410X.2007.07387.x.

45.

Nuclear medicine UK: signs of progress.

Ell PJ.

Cancer Imaging. 2004 Feb 7;4(2):51. doi: 10.1102/1470-7330.2003.0034. No abstract available.

46.

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.

Stone JM, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan RA, Krystal JH, Ell PJ, Pilowsky LS.

Psychopharmacology (Berl). 2008 Apr;197(3):401-8. doi: 10.1007/s00213-007-1047-x. Epub 2008 Jan 5.

PMID:
18176855
47.

Long-term estrogen therapy and 5-HT(2A) receptor binding in postmenopausal women; a single photon emission tomography (SPET) study.

Compton J, Travis MJ, Norbury R, Erlandsson K, van Amelsvoort T, Daly E, Waddington W, Matthiasson P, Eersels JL, Whitehead M, Kerwin RW, Ell PJ, Murphy DG.

Horm Behav. 2008 Jan;53(1):61-8. Epub 2007 Sep 16.

PMID:
17956758
48.
49.

Cardiac 82Rubidium PET/CT: initial European experience.

Groves AM, Speechly-Dick ME, Dickson JC, Kayani I, Endozo R, Blanchard P, Shastry M, Prvulovich E, Waddington WA, Ben-Haim S, Bomanji JB, McEwan JR, Ell PJ.

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1965-72. Epub 2007 Aug 31.

PMID:
17768620
50.

Non-[18F]FDG PET in clinical oncology.

Groves AM, Win T, Haim SB, Ell PJ.

Lancet Oncol. 2007 Sep;8(9):822-30. Review.

PMID:
17765191

Supplemental Content

Support Center